Royal Bank of Canada
AVIR icon

Royal Bank of Canada’s Atea Pharmaceuticals AVIR Stock Holding History

Royal Bank of Canada’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1K Sell
282
-1,658
-85% -$7.61K ﹤0.01% 6823
2025
Q4 		$7K Sell
1,940
-299,937
-99% -$953K ﹤0.01% 6557
2025
Q3 		$876K Buy
301,877
+289,647
+2,368% +$989K ﹤0.01% 4082
2025
Q2 		$43K Buy
12,230
+4,158
+52% +$12.4K ﹤0.01% 5982
2025
Q1 		$24K Sell
8,072
-2,771
-26% -$8.65K ﹤0.01% 5850
2024
Q4 		$37K Buy
10,843
+715
+7% +$2.38K ﹤0.01% 5834
2024
Q3 		$34K Buy
10,128
+2,871
+40% +$10.4K ﹤0.01% 5863
2024
Q2 		$24K Buy
7,257
+4,087
+129% +$15.2K ﹤0.01% 5983
2024
Q1 		$13K Sell
3,170
-26,439
-89% -$103K ﹤0.01% 6087
2023
Q4 		$91K Buy
29,609
+15,585
+111% +$47.2K ﹤0.01% 5668
2023
Q3 		$42K Buy
14,024
+6,026
+75% +$20.5K ﹤0.01% 5866
2023
Q2 		$30K Buy
7,998
+2,224
+39% +$8.33K ﹤0.01% 6004
2023
Q1 		$19K Sell
5,774
-4,890
-46% -$19.8K ﹤0.01% 6041
2022
Q4 		$52K Buy
10,664
+6,128
+135% +$31K ﹤0.01% 5849
2022
Q3 		$26K Buy
4,536
+2,507
+124% +$19.2K ﹤0.01% 6038
2022
Q2 		$15K Sell
2,029
-3,539
-64% -$24.2K ﹤0.01% 6212
2022
Q1 		$41K Sell
5,568
-5,681
-51% -$38.6K ﹤0.01% 6214
2021
Q4 		$100K Buy
11,249
+3,002
+36% +$46.8K ﹤0.01% 5933
2021
Q3 		$290K Buy
8,247
+2,090
+34% +$58K ﹤0.01% 4808
2021
Q2 		$133K Buy
6,157
+5,180
+530% +$156K ﹤0.01% 5409
2021
Q1 		$60K Buy
977
+615
+170% +$41.5K ﹤0.01% 5779
2020
Q4 		$15K Buy
+362
New +$11.7K ﹤0.01% 6186

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Royal Bank of Canada's AVIR Position: Q1 2026 in Review

Royal Bank of Canada reduced its Atea Pharmaceuticals (AVIR) stake by 85% in Q1 2026, selling an estimated $7.61K and leaving 282 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #6823.

Royal Bank of Canada first reported a position in AVIR in Q4 2020 and has held it in 22 quarters since. The position peaked at $876K in Q3 2025. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

  • Royal Bank of Canada held 282 shares of Atea Pharmaceuticals worth $1K as of Q1 2026.
  • Royal Bank of Canada sold 1,658 Atea Pharmaceuticals shares in Q1 2026, an estimated $7.61K.
  • Atea Pharmaceuticals made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6823 holding.
  • Royal Bank of Canada first reported a position in Atea Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
  • Royal Bank of Canada's Atea Pharmaceuticals position peaked at $876K in Q3 2025.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.